Gli anticoagulanti di ultima generazione
Download
1 / 24

Gli anticoagulanti di ultima generazione - PowerPoint PPT Presentation


  • 127 Views
  • Uploaded on

Gli anticoagulanti di ultima generazione. Ida Martinelli Centro Emofilia e Trombosi A. Bianchi Bonomi Fondazione IRCCS Ca’ Granda - Ospedale Maggiore Policlinico Milano. THE BURDEN OF THE DISEASE. Venous thromboembolism (VTE) is the 3 rd most common type of cardiovascular disease

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about ' Gli anticoagulanti di ultima generazione' - rosina


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
Gli anticoagulanti di ultima generazione

Gli anticoagulanti di ultima generazione

Ida Martinelli

Centro Emofilia e Trombosi A. Bianchi Bonomi

Fondazione IRCCS Ca’ Granda - Ospedale Maggiore Policlinico Milano


The burden of the disease
THE BURDEN OF THE DISEASE

  • Venous thromboembolism (VTE) is the 3rd most common type of cardiovascular disease

  • VTE causes over 500.000 deaths in Europe and 300.000 deaths in the United States each year

  • Annual deaths attributable to VTE are estimated to exceed the combined number of deaths from breast and prostate cancers, AIDS, and traffic accidents

  • Total estimated cost for VTE-associated care = EUR 3.1 billion per year


Achievements with traditional antithrombotic agents
ACHIEVEMENTS WITH TRADITIONAL ANTITHROMBOTIC AGENTS

  • Heparins (UFH and LMWH) reduce by about 60% the incidence of venous thromboembolism (VTE) after high-risk surgery

  • Vitamin K antagonists reduce by more than 90% VTE recurrence

  • Vitamin K antagonists reduce by about 60% the rate of stroke in patients with atrial fibrillation or artificial valves

  • Aspirin and clopidogrel reduce by about 50% the rate of stent thrombosis


Limits of traditional anticoagulants
LIMITS OF TRADITIONAL ANTICOAGULANTS

  • Slow onset of action (warfarin)  need for bridging

  • Need for laboratory monitoring (unfractionated heparin, warfarin)

  • Need for parenteral administration (heparins)

  • Non-hemorragic adverse effects, such as heparin induced thrombocytopenia, osteoporosis (heparins)


Limits of traditional anticoagulants1
LIMITS OF TRADITIONAL ANTICOAGULANTS

  • Interindividual variability in dosing requirements (warfarin)

  • Food and drug interactions (warfarin)

  • Reduced synthesis of all vitamin-K dependent proteins (risk of skin necrosis in protein C or S deficiency) (warfarin)


New anticoagulants
New anticoagulants

TTP889

TF/VIIa

TFPI (tifacogin)

NAPc2

IX

X

APC (drotrecogin alfa)

sTM (ART-123)

IXa

VIIIa

  • Oral - DIRECT

    • Rivaroxaban

    • Apixaban

    • Edoxaban

    • Betrixaban

    • YM150

  • Parenteral - INDIRECT

    • Fondaparinux

    • Idraparinux

    • Biotinylated idraparinux

    • ULMWH

Va

Xa

  • Oral – DIRECT

    • Dabigatran

II

IIa

Fibrinogen

Fibrin

adapted from Bates Br J Haematol 2006


New Oral Anticoagulants:

pharmacologic properties


STEPS OF CLINICAL EVALUATION OF NEW ORAL ANTICOAGULANTS

  • First prevention of VTE in major orthopedic surgery

  • Second treatment of VTE

  • Third atrial fibrillation, acute coronary syndromes



Cumulative results of phase 3 trials in vte prevention in high risk orthopedic surgery
CUMULATIVE RESULTS OF PHASE 3 for VTE PreventionTRIALS IN VTE PREVENTIONIN HIGH-RISK ORTHOPEDIC SURGERY

Oral dabigatran, rivaroxaban and apixaban, given once daily starting after surgery, are at least as effective or more effective than subcutaneous enoxaparin in patients undergoing high-risk orthopedic surgery


REgulation of Coagulation in major Orthopaedic surgery reducing the Risk of DVT and PELassen et al, N Engl J Med 2008:358; 2776

Efficacy: Total VTE (primary endpoint)

RECORD 2

RECORD 3

RECORD 1

Rivaroxaban 10 mgEnoxaparin 40 mg


Pooled analysis of rivarobaxan in vte prophylaxis

POOLED ANALYSIS OF RIVAROBAXAN reducing the Risk of DVT and PE IN VTE PROPHYLAXIS

More than 10.000 patients studied in 4 randomized trials

56% reduction in symptomatic VTE and mortality

No increased risk of bleeding


Phase 3 Clinical Trials of New Oral Anticoagulants ( reducing the Risk of DVT and PEvs. Enoxaparin)

in Total Hip Replacement (THR) and Total Knee Replacement (TKR)

RECORD-1

RECORD-2

Rivaroxaban

(Xa inhibitor)

RECORD-3

RECORD-4

RE-NOVATE (220 mg)

RE-NOVATE (150 mg)

Dabigatran

(thrombininhibitor)

RE-MODEL (220 mg)

RE-MODEL (150 mg)

ADVANCE-1

Apixaban

(Xa inhibitor)

ADVANCE-2

- 15

- 10

- 5

0

5

10

15

Absolute risk difference (%)


Phase III Randomized Controlled Trials of New Anticoagulants for Indications Other Than VTE Prevention


RE-COVER for Indications Other Than

N Engl J Med 2009


RE-COVER, N Engl J Med 2009 for Indications Other Than


EINSTEIN for Indications Other Than

N Engl J Med 2010


EINSTEIN, N Engl J Med 2010 for Indications Other Than


EINSTEIN-PE, N Engl J Med 2012 for Indications Other Than



New oral anticoagulants advantages
New Oral Anticoagulants - for Indications Other Than ADVANTAGES


Unproven compliance in daily clinical practice for Indications Other Than

More expensive than warfarin

Unknown safety after years of administration

New Oral Anticoagulants - CONCERNS


Contraindicated if renal or liver insufficiency for Indications Other Than

Difficult to be detected in patients plasma in case of emergency

No antidote

Caution when combined with ASA

New Oral Anticoagulants - CONCERNS


Personal opinion
Personal opinion for Indications Other Than

“Fixed” doses are not always better for any patient

Phase IV independent clinical trials are needed (risks and benefits in daily clinical practice and in patients excluded from phase III trials)


ad